GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » Tangible Book per Share

EOLS (Evolus) Tangible Book per Share : $-1.20 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Evolus's tangible book value per share for the quarter that ended in Mar. 2025 was $-1.20.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Evolus Tangible Book per Share Historical Data

The historical data trend for Evolus's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Tangible Book per Share Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.43 0.18 -0.91 -1.54 -1.02

Evolus Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -0.76 -0.98 -1.02 -1.20

Competitive Comparison of Evolus's Tangible Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Evolus's Price-to-Tangible-Book falls into.


;
;

Evolus Tangible Book per Share Calculation

Evolus's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(5.522-0-69.962)/63.498
=-1.01

Evolus's Tangible Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-6.604-0-70.567)/64.449
=-1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Evolus  (NAS:EOLS) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Evolus Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Evolus's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Executives
David Moatazedi director, officer: See Remarks C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Tomoko Yamagishi-dressler officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Sandra Beaver officer: Chief Financial Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar officer: See Remarks 1618 STATION STREET, VANCOUVER A1 V6A 1B6
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
Vikram Malik director 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Medytox Inc. 10 percent owner 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Alphaeon 1 Llc 10 percent owner 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman director 8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank director C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail officer: See Remarks 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Crystal Muilenburg officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart director 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660